ATE413183T1 - Verwendung von laminarin in der behandlung von krebs - Google Patents

Verwendung von laminarin in der behandlung von krebs

Info

Publication number
ATE413183T1
ATE413183T1 AT02787872T AT02787872T ATE413183T1 AT E413183 T1 ATE413183 T1 AT E413183T1 AT 02787872 T AT02787872 T AT 02787872T AT 02787872 T AT02787872 T AT 02787872T AT E413183 T1 ATE413183 T1 AT E413183T1
Authority
AT
Austria
Prior art keywords
cancer
treatment
laminarin
cancers
immunostimulant
Prior art date
Application number
AT02787872T
Other languages
English (en)
Inventor
Jean-Claude Yvin
Vaclav Vetvicka
Original Assignee
Goemar Lab Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goemar Lab Sa filed Critical Goemar Lab Sa
Application granted granted Critical
Publication of ATE413183T1 publication Critical patent/ATE413183T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
AT02787872T 2001-11-30 2002-11-29 Verwendung von laminarin in der behandlung von krebs ATE413183T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/999,202 US6660722B2 (en) 2001-11-30 2001-11-30 Therapeutical treatments

Publications (1)

Publication Number Publication Date
ATE413183T1 true ATE413183T1 (de) 2008-11-15

Family

ID=25546011

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02787872T ATE413183T1 (de) 2001-11-30 2002-11-29 Verwendung von laminarin in der behandlung von krebs

Country Status (11)

Country Link
US (1) US6660722B2 (de)
EP (1) EP1448215B1 (de)
JP (1) JP4633361B2 (de)
KR (1) KR20040096498A (de)
CN (1) CN100558369C (de)
AT (1) ATE413183T1 (de)
AU (1) AU2002352187A1 (de)
CA (1) CA2468314C (de)
DE (1) DE60229767D1 (de)
RU (1) RU2004119854A (de)
WO (1) WO2003045414A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7671040B2 (en) * 2003-09-23 2010-03-02 Laboratoires Goemar S.A. Chemotherapeutic antineoplastic treatment
US7070778B2 (en) 2003-10-30 2006-07-04 Laboratoire Goemar Sa Therapeutical combination against cancer
US20050220846A1 (en) * 2004-04-05 2005-10-06 Puntenney Steven B Use of beta-1,3 (4)-endoglucanohydrolase, beta-1,3 (4) glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function
ATE498323T1 (de) * 2005-05-18 2011-03-15 Goemar Lab Sa Laminarin-enthaltende lebensmittel
FR2885811B1 (fr) * 2005-05-18 2007-08-10 Goemar Lab Sa Medicament a base de laminarine ou d'oligolaminarines pour le traitement des hepatites virales
FR2885812B1 (fr) * 2005-05-18 2007-07-27 Goemar Lab Sa Medicament a base de laminarine ou d'oligolaminarines pour le traitement de la septicemie et du choc septique
US20090148414A1 (en) * 2005-11-21 2009-06-11 Bioatlantis Limited Novel Composition to Improve Gut Health and Animal Performance and Methods of Making the Same
FR2899815B1 (fr) * 2006-04-14 2008-07-11 Goemar Lab Sa Nouveaux medicaments pour les traitements contre les retrovirus
FR2909553B1 (fr) * 2006-12-08 2009-03-06 Bio Serae Lab Oligo-b(1-3)-glucanes a effet inhibiteur des reactions allergiques,et applications.
FR2910322B1 (fr) * 2006-12-22 2009-10-30 Mer Soc Par Actions Simplifiee Utilisation d'oligo-b-(1,3)-glucanes modifies pour le traite traitement de maladies du systeme immunitaire, oligo-b-(1,3) glucane-(1,3)-mannose, oligo-b-(1,3)-glucane-(1,3)-mannitol et leurs derives, ...
NL1036661C2 (en) * 2009-03-04 2010-09-07 Serrix B V Anti-fungal compounds & compositions.
HUE056825T2 (hu) * 2009-05-21 2022-03-28 Bioatlantis Ltd A gasztrointesztinális egészség, immunitás és teljesítmény javítása diétás beavatkozással
JP5968643B2 (ja) * 2012-02-22 2016-08-10 日本メナード化粧品株式会社 メラノサイト分化誘導抑制剤
EP2975937A1 (de) 2013-03-20 2016-01-27 Bioatlantis Limited Nichtnematizide zusammensetzung und verwendung davon
ES2656390T3 (es) 2014-02-12 2018-02-27 Omnigen Research, Llc Composición y método para promover la reducción de estrés por calor en animales
LT6145B (lt) 2014-04-14 2015-04-27 Uab "Biocentras" TERAPINĖ ß-GLIUKANŲ KOMPOZICIJA, MODULIUOJANTI ŽMOGAUS IMUNINĘ SISTEMĄ IR INICIJUOJANTI VĖŽINIŲ LĄSTELIŲ ARDYMĄ
CN105147732A (zh) * 2015-10-26 2015-12-16 北京百生康生物科技有限公司 鳄鱼血多糖在乳腺癌治疗中的应用
CN111544592B (zh) * 2020-03-13 2022-05-03 中山大学附属第一医院 模式识别受体Dectin-1抑制剂对受体移植物的免疫保护及诱导免疫耐受的应用
WO2023002252A1 (en) 2021-07-21 2023-01-26 Bioatlantis Limited Composition comprising beta-glucans and alpha-fucans for improving gut health and animal performance and methods of making the same
WO2023112454A1 (ja) * 2021-12-16 2023-06-22 学校法人東京理科大学 腸管腫瘍抑制剤、ｐｇｅ２産生抑制剤、及びｉｌ－２２ｂｐ産生促進剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0742234B2 (ja) * 1989-02-10 1995-05-10 株式会社紀文食品 逆転写酵素阻害剤
IL108951A0 (en) * 1994-03-13 1994-06-24 Hadasit Med Res Service Pharmaceutical compositions containing polysulfated polysaccharides
JP2002012552A (ja) * 2000-04-27 2002-01-15 Okamoto Denki Kk 動物・ヒト用免疫賦活調整剤及び動物・ヒトの感染症や皮膚病、癌の予防・治療方法
FR2816213B1 (fr) * 2000-11-03 2005-04-22 Goemar Lab Sa Medicament anti-inflammatoire et cicatrisant

Also Published As

Publication number Publication date
WO2003045414A2 (en) 2003-06-05
CN1596118A (zh) 2005-03-16
US6660722B2 (en) 2003-12-09
KR20040096498A (ko) 2004-11-16
CA2468314A1 (en) 2003-06-05
AU2002352187A8 (en) 2003-06-10
CA2468314C (en) 2010-10-19
EP1448215B1 (de) 2008-11-05
RU2004119854A (ru) 2005-03-27
DE60229767D1 (de) 2008-12-18
CN100558369C (zh) 2009-11-11
EP1448215A2 (de) 2004-08-25
US20030119780A1 (en) 2003-06-26
AU2002352187A1 (en) 2003-06-10
WO2003045414A3 (en) 2003-10-16
JP4633361B2 (ja) 2011-02-16
JP2005510543A (ja) 2005-04-21

Similar Documents

Publication Publication Date Title
DE60229767D1 (de) Verwendung von laminarin in der behandlung von krebs
HRP20050436A2 (en) Quinolinyl-pyrrolopyrazoles
CY1107838T1 (el) Παραγωγα αδαμαντανιου για τη θεραπεια φλεγμονωδων, ανοσολογικων και καρδιαγγειακων ασθενειων
CY1105552T1 (el) Βαλπροϊκο οξυ και παραγωγα για την συνδυαστικη θεραπευτικη αντιμετωπιση ανθρωπινων καρκινων και για την αντιμετωπιση της μεταστασης ογκων και ελαχιστης υπολειμματικης νοσου
CY1108765T1 (el) ΑΓΩΓΗ ME ΑΝΤΙΣΩΜΑΤΑ ANTI-ErbB2
BR0112591A (pt) Derivados de acridina e sua aplicação como medicamento
NO20022065D0 (no) Terapeutisk anvendelse
NO20032027D0 (no) Effektive antitumorbehandlinger
PT1390371E (pt) Oxazolo- e furopirimidinas e sua utilizacao em medicamentos contra tumores
EP1706423B8 (de) Therapeutische und diagnostische anti-hsp 70-antikörper
DE602004016376D1 (de) Kombination von et-743 mit 5-fluorouracil pro-drugs zur behandlung von krebs
BR0112807A (pt) Derivados de indol e sua aplicação como medicamento
DE60311788D1 (de) Kombinationstherapie zur behandlung von krebs
WO2005027936A3 (en) Pharmaceutical compositions and therapeutical treatment with oligo-beta-(1, 3)-glucans
RU93042874A (ru) Соединения полипептидной природы, способ их получения, композиция на их основе, их применение в противоопухолевой терапии
CY1108919T1 (el) Θεραπευτικη αγωγη νεφροκυτταρικου καρκινωματος
DE60331827D1 (de) Zusammensetzungen für die radioimmuntherapie von gehirn-tumoren
ATE345805T1 (de) Calciumtrifluoracetat mit zytotoxischer wirkung
DE50303513D1 (de) Mittel mit zerstörender wirkung auf maligne tumore sowie verfahren zu seiner herstellung
DK0455769T3 (da) Anvendelse af 7-OH-1,2-benzopyron til fremstilling af et lægemiddel til behandling af magline tumore r hos mennesker
EA200600987A1 (ru) Применение сирамезина в лечении злокачественных опухолей
ATE411313T1 (de) Neue makrocyclen zur behandlung von krebserkrankungen
RU2001106336A (ru) Способ комбинированного лечения рака пищевода грудного отдела
RU2001112731A (ru) Способ лечения онкологических больных
RU2001125198A (ru) Способ щадящей терапии опухолевых заболеваний

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties